Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis
Ustekinumab-ttwe's equivalence to its reference biologic ustekinumab creates another treatment option for patients with moderate- to- severe plaque psoriasis.
Authors
- Christopher Giuliano (ORCID: https://orcid.org/0000-0002-0540-785X)
- Pramodini Kale-Pradhan (ORCID: https://orcid.org/0000-0002-8729-7710)
- Bianca Lindecker
Institutions
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1177/10600280251375990
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00